List of Excipients in Branded Drug GALANTAMINE HYDROBROMIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Patriot Pharmaceuticals LLC	GALANTAMINE HYDROBROMIDE	galantamine hydrobromide	10147-0881	CELLULOSE, MICROCRYSTALLINE
Patriot Pharmaceuticals LLC	GALANTAMINE HYDROBROMIDE	galantamine hydrobromide	10147-0881	CROSPOVIDONE
Patriot Pharmaceuticals LLC	GALANTAMINE HYDROBROMIDE	galantamine hydrobromide	10147-0881	FERRIC OXIDE YELLOW
Patriot Pharmaceuticals LLC	GALANTAMINE HYDROBROMIDE	galantamine hydrobromide	10147-0881	HYPROMELLOSE

Generic Drugs Containing GALANTAMINE HYDROBROMIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	galantamine hydrobromide	0054-0137	METHYLPARABEN
Hikma Pharmaceuticals USA Inc	galantamine hydrobromide	0054-0137	PROPYLPARABEN
Hikma Pharmaceuticals USA Inc	galantamine hydrobromide	0054-0137	SACCHARIN SODIUM
Hikma Pharmaceuticals USA Inc	galantamine hydrobromide	0054-0137	WATER

What are the Most Frequently-Used Excipients in GALANTAMINE HYDROBROMIDE?

# Of NDCs	Excipient
2	FD&C YELLOW NO. 6
5	FERRIC OXIDE RED
2	FERRIC OXIDE YELLOW
8	GELATIN

Galantamine Hydrobromide Excipient Strategy and Commercial Opportunities

Last updated: September 16, 2026

Galantamine hydrobromide is a mature oral Alzheimer’s medicine with limited opportunity in the active pharmaceutical ingredient itself and greater potential in formulation, adherence, taste masking, modified release, and differentiated delivery. The core commercial market is generic and price-sensitive. The strongest product opportunities are once-daily formulations, liquid or orally disintegrating dosage forms for patients with swallowing difficulty, and formulations that reduce gastrointestinal adverse effects while preserving galantamine exposure.

What is the market position of galantamine hydrobromide?

Galantamine hydrobromide is an acetylcholinesterase inhibitor approved for the treatment of mild-to-moderate dementia of the Alzheimer’s type. It is marketed in immediate-release tablets, an oral solution, and extended-release capsules. The branded product was originally sold as Razadyne, formerly Reminyl, by Janssen and related commercial partners. Generic galantamine products are widely available in the United States and other regulated markets.

Attribute	Galantamine hydrobromide
Therapeutic class	Acetylcholinesterase inhibitor
Main indication	Mild-to-moderate Alzheimer’s dementia
Common immediate-release strengths	4 mg, 8 mg, 12 mg
Common extended-release strengths	8 mg, 16 mg, 24 mg
Oral solution strength	4 mg/mL
Typical dosing approach	Twice daily for immediate release; once daily for extended release
Primary patient population	Older adults with cognitive impairment
Principal formulation issues	Gastrointestinal tolerability, swallowing difficulty, adherence, dose titration
Regulatory status	Established small-molecule prescription product
Biosimilar exposure	None; galantamine is not a biologic

Galantamine is usually initiated at a low dose and titrated. The approved labeling recommends administration with food and adequate hydration to reduce adverse effects such as nausea and vomiting. These instructions create formulation opportunities around tolerability and adherence rather than basic pharmacological differentiation (FDA, 2023a).

What excipients are used in galantamine hydrobromide products?

The principal commercial formulations use conventional oral solid-dosage excipients. The exact composition varies by manufacturer and dosage form.

Immediate-release tablets

Commercial galantamine tablets generally use combinations of:

• Microcrystalline cellulose as a diluent and compression aid
• Lactose monohydrate as a filler
• Crospovidone as a disintegrant
• Colloidal silicon dioxide as a glidant
• Magnesium stearate as a lubricant
• Hypromellose and coating polymers
• Talc and titanium dioxide in the film coating
• Colorants where required for strength differentiation

The formulation objective is rapid tablet disintegration and reproducible dissolution. Because galantamine hydrobromide is water-soluble, the formulation does not normally require a complex solubilization system. Excessive hydrophobic lubricant or an overly dense tablet matrix can slow wetting and dissolution, making lubricant concentration and compression force important development variables.

Oral solution

The branded oral solution contains a water-based vehicle and preservative system. Public labeling identifies excipients including methylparaben, propylparaben, sodium benzoate, sorbitol, and purified water, although composition can vary among products and markets (FDA, 2023b).

The commercial advantages of the solution are dose flexibility and easier administration for patients who cannot swallow tablets or capsules. The main technical constraints are:

• Chemical stability in an aqueous environment
• Microbiological preservation
• Taste and mouthfeel
• Accurate dosing at low volumes
• Compatibility with measuring devices
• Sorbitol-related gastrointestinal effects
• Labeling requirements for preservatives and sweeteners

A preservative-free multidose product would require a validated packaging and microbiological-control strategy. A single-dose or unit-dose presentation could reduce preservative exposure but would increase packaging cost.

Extended-release capsules

Extended-release galantamine capsules generally contain multiparticulate beads or pellets. The release profile is controlled through polymer-coated particles rather than a simple immediate-release tablet matrix. Common functional excipients for this platform include:

• Sucrose or microcrystalline cellulose starter cores
• Hypromellose or other binder polymers
• Ethylcellulose or related water-insoluble coating polymers
• Hypromellose-based film coatings
• Talc or anti-tacking agents
• Capsule-shell gelatin or hypromellose

The primary development challenge is achieving a reproducible 24-hour release profile across dose strengths. The product must avoid both dose dumping and excessive residual drug release at the end of the dosing interval. Multiparticulate systems can offer more consistent gastrointestinal distribution than a single monolithic matrix, but they require tighter control of pellet size, coating weight gain, coating defects, and blend uniformity.

Which excipient strategies offer the strongest commercial potential?

The most attractive strategies address a documented clinical or commercial problem. A new excipient has limited value if it only replaces an established filler or lubricant without improving product performance.

1. Taste masking for oral liquids and orally disintegrating tablets

Galantamine hydrobromide is suitable for liquid and orally disintegrating formats, but taste is a material barrier for chronic use. Taste-masking approaches include:

• Ion-exchange resins
• Polymer microencapsulation
• Lipid or wax coating
• Cyclodextrin complexation
• Multiparticulate coating
• Sweetener and flavor systems
• Effervescent or rapidly dispersing platforms

Ion-exchange resin complexes may be attractive where the formulation must release galantamine in the gastrointestinal tract but limit immediate exposure in the oral cavity. The risk is incomplete drug release or altered pharmacokinetics. Taste-masking excipients therefore require dissolution testing under both oral and gastrointestinal conditions.

2. Orally disintegrating tablets

An orally disintegrating tablet could target patients with dysphagia, caregivers administering medication, and patients who resist conventional tablets. Candidate excipient systems include crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, mannitol, and directly compressible co-processed excipients.

Mannitol can improve mouthfeel and cooling sensation. Crospovidone can support rapid disintegration without producing excessive viscosity. The formulation must balance:

• Mechanical strength during packaging and transport
• Disintegration time
• Friability
• Taste masking
• Moisture sensitivity
• Dose uniformity across 4 mg, 8 mg, and 12 mg strengths

An orally disintegrating product is more likely to obtain commercial differentiation through a 505(b)(2) pathway or an equivalent jurisdictional route if it demonstrates a meaningful dosage-form advantage. A conventional generic ODT may face substantial price competition.

3. Modified-release formulations

Once-daily dosing is already established through extended-release capsules, which limits the value of a simple once-daily reformulation. A stronger opportunity would combine once-daily dosing with another advantage, such as:

• Lower peak concentration
• Reduced nausea during dose escalation
• Improved exposure consistency
• Sprinkle administration
• Administration through feeding tubes
• Reduced capsule size
• Lower pill burden through combination therapy

Hydrophilic matrix systems using hydroxypropyl methylcellulose can be simpler to manufacture than coated pellets, but they must control dose-dumping risk and food effects. Multiparticulate systems are more adaptable to sprinkle products and can be engineered for a smoother release profile. The commercial choice depends on manufacturing scale, target market, and regulatory strategy.

4. Low-moisture and high-stability formulations

Older patients often use multiple medicines and may store products in non-ideal conditions. Moisture-resistant blister packaging, desiccant-equipped bottles, and low-moisture excipient systems can protect tablet hardness, dissolution, and coating integrity.

Galantamine products should be evaluated for:

• Hygroscopicity of the active and excipients
• Water activity
• Tablet aging
• Coating cracking
• Dissolution drift
• Interaction with PVC, PVdC, aluminum, and high-barrier films

A stability-led product strategy can be valuable in hot and humid markets, particularly where distribution infrastructure is less controlled.

What formulations are protected by galantamine hydrobromide patents?

The original innovator formulation estate covered galantamine products and related pharmaceutical compositions, but the main commercial exclusivity period has ended. Galantamine is now a mature generic molecule in the United States.

The relevant intellectual-property categories include:

IP category	Commercial relevance
Composition-of-matter patents	Historically protected galantamine and related compounds; expired or commercially exhausted
Immediate-release formulations	Limited current blocking value where generic products are approved
Extended-release formulations	Potentially relevant only if a particular release architecture has unexpired claims
Oral liquid formulations	Opportunity for formulation patents covering taste, stability, preservatives, or packaging
ODT and dysphagia formulations	Potentially protectable through composition, process, and performance claims
Manufacturing processes	May protect pellet coating, particle engineering, or impurity control
Method-of-use patents	Limited scope because the principal Alzheimer’s use is established
Device and packaging patents	Possible protection for unit-dose, dispenser, or caregiver-administered products

Patentability is stronger where the formulation provides a measurable technical effect, such as a defined dissolution profile, improved stability, reduced bitterness, lower peak exposure, or improved administration through a feeding tube. Broad claims covering galantamine plus routine excipients are vulnerable to obviousness and enablement challenges.

What is the FDA regulatory status and Orange Book position?

Galantamine hydrobromide is an FDA-approved prescription drug. The immediate-release and extended-release dosage forms are regulated as conventional small-molecule products. Generic applicants generally rely on abbreviated new drug applications and must demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference product.

The Orange Book has historically listed the branded galantamine reference products and associated patent or exclusivity information. The practical market position is now generic competition rather than branded patent protection. Applicants pursuing a conventional generic product face a different regulatory burden from sponsors developing a new dosage form:

Development route	Typical objective	Main evidence burden
ANDA	Generic tablet, solution, or capsule	Pharmaceutical equivalence, bioequivalence, quality
505(b)(2) NDA	ODT, novel liquid, alternative release system	Bridging studies, CMC, clinical or pharmacokinetic justification
Full NDA	New therapeutic or delivery concept	Expanded nonclinical and clinical package
OTC switch	Consumer-directed use	Not commercially established for Alzheimer’s treatment

The key regulatory risk for a modified formulation is failure to demonstrate equivalence in exposure, food effect, dose proportionality, or titration performance. FDA labeling also requires attention to renal and hepatic impairment, drug interactions, and the titration schedule.

When does galantamine hydrobromide lose exclusivity?

The original exclusivity period has already expired, and generic galantamine products are commercially established. The relevant commercial question is no longer the basic loss of exclusivity. It is whether a differentiated formulation can obtain independent protection and command a premium.

A new product could pursue:

1. A formulation patent with claims directed to release rate, taste masking, stability, or administration.
2. Regulatory exclusivity tied to a qualifying new clinical investigation.
3. A 505(b)(2) strategy based on a new dosage form or delivery method.
4. Trademark and trade-dress protection for caregiver-oriented packaging.
5. Manufacturing know-how that is difficult to replicate even without broad patent coverage.

Any new patent must be assessed against the extensive prior art surrounding acetylcholinesterase inhibitors, oral multiparticulates, orally disintegrating tablets, preservative systems, and taste-masking technologies.

Which companies are challenging the galantamine market?

The market is primarily challenged by generic manufacturers rather than by biosimilar developers. Companies that have historically commercialized or filed generic galantamine products include large U.S. and international generic manufacturers, contract development and manufacturing organizations, and regional suppliers.

The principal competitive dimensions are:

• API cost and supply security
• Tablet and capsule manufacturing yield
• Extended-release pellet coating capacity
• Regulatory history
• Ability to supply multiple strengths
• Hospital and pharmacy contracting
• Stability in global climates
• Packaging cost
• Availability of liquid and sprinkle presentations

The generic market is fragmented at the product level but concentrated among suppliers with reliable regulatory and manufacturing capacity. A new entrant with only a conventional immediate-release tablet is likely to compete primarily on price.

What generic entry risks exist for a new galantamine product?

Generic entry risk is high for standard tablets and conventional capsules. A sponsor seeking premium pricing should avoid relying on an unprotected dosage-form concept.

The main risks are:

• Rapid price erosion after approval
• Multiple approved ANDAs
• Substitution at the pharmacy level
• Limited prescriber loyalty to a mature molecule
• Weak differentiation between conventional products
• Difficulty securing reimbursement for a reformulated product
• Low willingness to pay for minor excipient changes
• Bioequivalence failure caused by modified release or food effects

Commercial protection improves when the product solves a specific administration problem and the advantage is visible to caregivers, pharmacists, or payers.

How does galantamine compare with donepezil and rivastigmine?

Galantamine competes mainly with donepezil and rivastigmine in Alzheimer’s dementia. The competitive distinction is dosage form and tolerability rather than a clearly superior disease-modifying effect.

Drug	Common dosage forms	Formulation opportunity	Competitive issue
Galantamine	IR tablets, oral solution, ER capsules	ODT, taste-masked liquid, sprinkle ER, smoother titration	Mature generic market
Donepezil	Tablets, ODT, oral solution in some markets	ODT and low-dose adherence products	Strong generic competition
Rivastigmine	Capsules, oral solution, transdermal patch	Patch optimization, oral films, liquid dosing	Patch provides non-oral differentiation

Rivastigmine’s transdermal patch creates a stronger non-oral benchmark. A galantamine sponsor would need a clear administration or tolerability advantage to displace established patch or tablet use.

What licensing and partnership opportunities exist?

Licensing opportunities are more likely to involve technology than the galantamine molecule. Potential deal targets include:

• Taste-masking platforms
• Multiparticulate coating technology
• Orally disintegrating tablet platforms
• High-barrier packaging
• Unit-dose liquid packaging
• Feeding-tube-compatible formulations
• Co-processed excipients for direct compression
• Global regulatory dossiers for emerging markets

A practical transaction structure could combine an excipient or delivery-platform license with a regional commercialization agreement. The asset should include freedom-to-operate analysis, scale-up data, dissolution methodology, stability data, and a defined regulatory pathway.

What manufacturing and IP barriers matter most?

The largest technical barrier is extended-release manufacturing. Consistent pellet coating requires control of:

• Core particle-size distribution
• Drug-layer uniformity
• Polymer coating thickness
• Spray rate and atomization
• Inlet and product temperature
• Residual solvent or moisture
• Pellet segregation during encapsulation

For liquid products, the critical controls are preservative effectiveness, assay uniformity, microbial limits, flavor stability, and container closure integrity.

For ODTs, manufacturing barriers include low-dose content uniformity, compression robustness, moisture control, and packaging that preserves rapid disintegration. These process controls can support trade-secret protection even when formulation patent claims are narrow.

What is the commercial outlook for galantamine hydrobromide excipients?

The commercial outlook is strongest in enabling technologies that improve administration rather than in commodity excipients. High-value opportunities include:

1. A taste-masked liquid with preservative and packaging advantages.
2. An ODT designed for dysphagia and caregiver administration.
3. A sprinkle-compatible extended-release multiparticulate.
4. A stable, low-cost product for hot and humid markets.
5. A co-processed excipient system that improves low-dose content uniformity.
6. A combination or coordinated-care package that reduces medication-management burden.

Commodity fillers, lubricants, and standard film-coating materials face intense competition and limited pricing power. A differentiated excipient platform can command better economics when it supports a protected formulation, reduces manufacturing failures, or enables a regulatory filing that competitors cannot quickly duplicate.

Revenue exposure

Galantamine revenue is exposed to:

• Generic price erosion
• Declining or stable use of symptomatic Alzheimer’s therapies
• Competition from donepezil and rivastigmine
• Changes in treatment guidelines
• Care-setting preferences
• Reimbursement substitution
• Future adoption of disease-modifying Alzheimer’s therapies

A formulation investment should therefore be sized against a mature-market profile. The most defensible strategy is a focused product with measurable adherence or administration benefits, not a broad capacity build based on historical branded sales.

Key Takeaways

• Galantamine hydrobromide is a mature generic Alzheimer’s medicine with limited standalone molecule-level exclusivity.
• The principal excipient opportunities are taste masking, orally disintegrating tablets, oral liquids, modified release, and moisture-protective packaging.
• Standard immediate-release tablets offer low differentiation and high generic-entry risk.
• Extended-release multiparticulates remain technically attractive but require strong process control and bioequivalence planning.
• A 505(b)(2) strategy may be appropriate for a genuinely differentiated dosage form.
• New patent value is strongest for measurable performance improvements, not routine excipient substitution.
• The leading commercial opportunities target dysphagia, caregiver administration, liquid dosing, feeding-tube use, and improved titration tolerability.
• No biosimilar pathway applies because galantamine is a small molecule.
• Excipient suppliers should prioritize enabling technologies with formulation, manufacturing, or regulatory value.

FAQs

Can galantamine hydrobromide be formulated as an orally disintegrating tablet?

Yes. An ODT can target patients with dysphagia, but taste masking, mechanical strength, moisture protection, and low-dose content uniformity must be controlled.

Is galantamine hydrobromide suitable for a feeding-tube formulation?

Potentially. A liquid or sprinkle-compatible multiparticulate product would require testing for tube passage, adsorption, dose recovery, clogging, and release-profile changes after administration.

Which excipient is best for galantamine taste masking?

No single excipient is universally optimal. Ion-exchange resins, polymer coatings, lipid barriers, and cyclodextrin systems should be screened against bitterness, drug release, manufacturability, and stability.

Can a new galantamine formulation obtain patent protection?

Yes, if the formulation produces a defensible technical effect, such as improved taste, stability, dissolution control, reduced peak exposure, or administration performance. Routine excipient combinations are less likely to support strong claims.

Is galantamine hydrobromide a good candidate for a premium generic?

Only with meaningful differentiation. A conventional tablet is unlikely to sustain a premium, while an ODT, taste-masked liquid, feeding-tube product, or improved extended-release system may support stronger commercial positioning.

References

1. U.S. Food and Drug Administration. (2023a). Razadyne (galantamine hydrobromide) prescribing information.
2. U.S. Food and Drug Administration. (2023b). Galantamine hydrobromide oral solution prescribing information.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. DailyMed. (2024). Galantamine hydrobromide tablet, extended-release capsule, and oral solution labeling. National Library of Medicine.
5. U.S. Food and Drug Administration. (2019). Guidance for industry: ANDAs for certain highly soluble, highly permeable drugs.
6. U.S. Food and Drug Administration. (2022). Guidance for industry: Bioavailability and bioequivalence studies submitted in NDAs or INDs: General considerations.